Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1962 2
1965 1
1968 4
1969 2
1970 3
1971 1
1972 6
1973 4
1974 1
1975 4
1976 1
1977 5
1978 1
1979 3
1980 3
1981 5
1982 6
1983 3
1984 8
1985 2
1986 3
1987 4
1988 11
1989 12
1990 11
1991 8
1992 12
1993 14
1994 20
1995 19
1996 28
1997 23
1998 30
1999 33
2000 29
2001 26
2002 26
2003 36
2004 23
2005 44
2006 31
2007 26
2008 31
2009 35
2010 25
2011 36
2012 53
2013 42
2014 46
2015 45
2016 50
2017 65
2018 70
2019 82
2020 73
2021 80
2022 47
2023 53
2024 76
2025 75
2026 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,407 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean masui h[au] (292 results)?
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Hihara M, Soeda J, Misumi T, Yamamoto K, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. Watanabe J, et al. Among authors: yasui h. JAMA. 2023 Apr 18;329(15):1271-1282. doi: 10.1001/jama.2023.4428. JAMA. 2023. PMID: 37071094 Free PMC article. Clinical Trial.
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Dib Bartolomeo M, Lonardi S, Tabernero J, Van Cutsem E, Janjigian YY, Oh DY, Xu J, Fang X, Shih CS, Bhagia P, Bang YJ; KEYNOTE-585 investigators. Shitara K, et al. Among authors: yasui h. Lancet Oncol. 2024 Feb;25(2):212-224. doi: 10.1016/S1470-2045(23)00541-7. Epub 2023 Dec 19. Lancet Oncol. 2024. PMID: 38134948 Clinical Trial.
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N. Kang YK, et al. Among authors: yasui h. Lancet Oncol. 2022 Feb;23(2):234-247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030335 Clinical Trial.
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.
Shitara K, Rha SY, Wyrwicz L, Oshima T, Karaseva N, Osipov M, Yasui H, Yabusaki H, Afanasyev S, Park YK, Al-Batran SE, Yoshikawa T, Yanez P, Pietrantonio F, Lonardi S, Fang X, Guan Y, Valderrama A, Leconte P, Bhagia P, Bang YJ; KEYNOTE-585 Investigators. Shitara K, et al. Among authors: yasui h. J Clin Oncol. 2025 Oct 10;43(29):3152-3159. doi: 10.1200/JCO-25-00486. Epub 2025 Aug 19. J Clin Oncol. 2025. PMID: 40829093 Clinical Trial.
Response.
Hozumi H, Kono M, Hasegawa H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Inui N, Nakamura Y, Yokomura K, Nakamura H, Suda T. Hozumi H, et al. Among authors: yasui h. Chest. 2021 Dec;160(6):e683-e685. doi: 10.1016/j.chest.2021.07.044. Chest. 2021. PMID: 34872693 No abstract available.
An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study.
Kadowaki S, Otsuka T, Minashi K, Nishina S, Yabusaki H, Inagaki C, Nishina T, Yasui H, Matsuoka H, Machida N, Tsuda M, Nagashima F, Hosaka H, Matsubara J, Arai H, Ida S, Kimijima Y, Matsuda Y, Muto M, Muro K. Kadowaki S, et al. Among authors: yasui h. Gastric Cancer. 2025 Sep;28(5):955-967. doi: 10.1007/s10120-025-01641-7. Epub 2025 Jul 9. Gastric Cancer. 2025. PMID: 40632416 Free PMC article.
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
Shitara K, Muro K, Watanabe J, Yamazaki K, Ohori H, Shiozawa M, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Mori I, Yamanaka K, Hihara M, Soeda J, Misumi T, Yamamoto K, Yamashita R, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. Shitara K, et al. Among authors: yasui h. Nat Med. 2024 Mar;30(3):730-739. doi: 10.1038/s41591-023-02791-w. Epub 2024 Feb 12. Nat Med. 2024. PMID: 38347302 Free PMC article.
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial.
Shiozawa M, Sunakawa Y, Watanabe T, Ota H, Yasui H, Yabuno T, Tei M, Kochi M, Manaka D, Ohori H, Yamaguchi T, Sagawa T, Kotaka M, Kubota Y, Sekikawa T, Nakamura M, Takeuchi M, Ichikawa W, Fujii M, Tsuji A. Shiozawa M, et al. Among authors: yasui h. Nat Commun. 2024 Nov 25;15(1):10217. doi: 10.1038/s41467-024-54460-2. Nat Commun. 2024. PMID: 39587053 Free PMC article. Clinical Trial.
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Kawazoe A, Yamaguchi K, Hamaguchi T, Narita Y, Boku S, Oshima T, Hara H, Hamamoto Y, Ishido K, Esaki T, Hosaka H, Yasui H, Koeda K, Nishina T, Tsuji Y, Fukagawa T, Goto M, Oki E, Sugimoto N, Matsuoka H, Yokoyama F, Yoshida T, Yoshida K, Oshima Y, Iwasa S. Kawazoe A, et al. Among authors: yasui h. Cancer Sci. 2025 Sep;116(9):2523-2536. doi: 10.1111/cas.70130. Epub 2025 Jul 6. Cancer Sci. 2025. PMID: 40618725 Free PMC article. Clinical Trial.
Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors.
Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, Taniguchi H, Sunakawa Y, Yamaguchi K, Kato K, Denda T, Nishina T, Takahashi N, Satoh T, Yasui H, Satake H, Oki E, Kato T, Ohta T, Matsuhashi N, Goto M, Okano N, Ohtsubo K, Yamazaki K, Yamashita R, Iida N, Yuasa M, Bando H, Yoshino T. Nakamura Y, et al. Among authors: yasui h. Nat Med. 2025 Jan;31(1):165-175. doi: 10.1038/s41591-024-03244-8. Epub 2024 Sep 16. Nat Med. 2025. PMID: 39284955 Free PMC article.
1,407 results